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Abstract
Background: The association of reproductive factors with hormone receptor (HR)-negative breast tumors remains
uncertain.
Methods: Within the EPIC cohort, Cox proportional hazards models were used to describe the relationships of
reproductive factors (menarcheal age, time between menarche and first pregnancy, parity, number of children, age
at first and last pregnancies, time since last full-term childbirth, breastfeeding, age at menopause, ever having an
abortion and use of oral contraceptives [OC]) with risk of ER-PR- (n = 998) and ER+PR+ (n = 3,567) breast tumors.
Results: A later first full-term childbirth was associated with increased risk of ER+PR+ tumors but not with risk of
ER-PR- tumors (≥35 vs. ≤19 years HR: 1.47 [95% CI 1.15-1.88] ptrend < 0.001 for ER+PR+ tumors; ≥35 vs. ≤19 years
HR: 0.93 [95% CI 0.53-1.65] ptrend = 0.96 for ER-PR- tumors; Phet = 0.03). The risk associations of menarcheal age, and
time period between menarche and first full-term childbirth with ER-PR-tumors were in the similar direction with
risk of ER+PR+ tumors (phet = 0.50), although weaker in magnitude and statistically only borderline significant. Other
parity related factors such as ever a full-term birth, number of births, age- and time since last birth were associated
only with ER+PR+ malignancies, however no statistical heterogeneity between breast cancer subtypes was observed.
Breastfeeding and OC use were generally not associated with breast cancer subtype risk.
Conclusion: Our study provides possible evidence that age at menarche, and time between menarche and first
full-term childbirth may be associated with the etiology of both HR-negative and HR-positive malignancies,
although the associations with HR-negative breast cancer were only borderline significant.
Keywords: ER-receptor, PR-receptor, Reproductive factors, Risk factors, Menopause, Parity, Oral contraceptive,
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Breast cancer is a complex and heterogeneous disease
with a variety of histo-pathological and molecular sub-
types with diverse clinical outcomes and relationships with
established risk factors [1-3]. The major sub-classification
of clinical breast tumors is based on the detection of
estrogen (ER) and progesterone (PR) receptors and guides
targeted therapies and provides important prognostic
information [4]. The presence or absence of hormone re-
ceptors, along with human epidermal growth factor-2
(HER2) also broadly correspond to more detailed mole-
cular subclassification of breast tumors, as determined by
microarray-based gene expression profiling coupled to
hierarchical clustering analyses [5-7]. In addition to the
clinical use of ER and PR, epidemiological data indicate that
the association of reproductive history with breast cancer
differs by the expression of ER and PR receptors [2].
Factors that influence the lifetime cumulative exposure
to hormones during reproductive life, such as the age at
menarche, age at first child-birth, time between age at me-
narche and first child birth, number of children, use of
oral contraceptives (OC) and breastfeeding, have been
suggested to be associated with risk of hormone receptor
(HR)-positive malignancies (ER-positive or joint ER+PR+)
[2,8-11]. However, distinct risk factors for HR-negative
(ER-negative, or joint ER-PR) cancer are debated [2,3,8,12]
and the etiologies of ER+PR+ and ER-PR- tumors remain
unclear.
The incidence of HR-negative disease drops remarkably
after menopause [13] suggesting that ovarian derived sex
steroid hormones do have an impact on HR-negative
tumors and recent studies are starting to show risk asso-
ciations of reproductive factors with HR-negative malig-
nancies [2,3]. In fact, opposite risk associations between
ER-PR- and ER+PR+tumors have been observed with par-
ity [11,14], age at first pregnancy [9] and breastfeeding
[11]. Nonetheless, due to the rarity and heterogeneous
nature of HR-negative breast tumors, epidemiological
studies have been hindered by small sample sizes resulting
in inconsistent risk associations between reproductive
factors and HR-negative disease [8,11,15,16].
The incidence of HR-negative disease drops remarkably
after menopause [13] suggesting that ovarian derived sex
steroid hormones do have an impact on HR-negative
tumors and recent studies are starting to show risk asso-
ciations of reproductive factors with HR-negative malig-
nancies [2,3]. In fact, opposite risk associations between
ER-PR- and ER+PR+ tumors have been observed with
parity [11,14], age at first pregnancy [9] and breastfeeding
[11]. Nonetheless, due to the rarity and heterogeneous
nature of HR-negative breast tumors, epidemiological
studies have been hindered by small sample sizes resulting
in inconsistent risk associations between reproductive fac-
tors and HR-negative disease [3,8,14,15].
Methods
The European Prospective Investigation into Cancer and
Nutrition (EPIC) is a multi-center prospective cohort
study designed to investigate the relationships between
diet, nutrition and metabolic factors and cancer, consis-
ting of approximately 360,000 women and 150,000 men
aged mostly between 25–70 years [16,17]. All parti-
cipants were enrolled between 1992 and 2000 and came
from 23 regional and national research centers located
in 10 western European countries: Denmark, France,
Italy, Germany, Greece Norway, Spain, Sweden, The
Netherlands and the United Kingdom. Extensive details
about the standardized procedures for recruitment, mea-
suring baseline anthropometry, questionnaires on current
habitual diet, reproductive and menstrual history, exo-
genous hormone use [OC and hormone replacement
therapy (HRT) use], medical history, lifetime smoking and
alcohol consumption history, occupation, level of educa-
tion and physical activity and biological sample collection
at study centers are given elsewhere [16,17]. All subjects
gave written informed consent. The Internal Review
Boards of the International Agency for Research on Cancer
and the local ethics committees in participating countries
approved the analyses based on EPIC participants.
Study participants
Of the approximately 360,000 female participants in EPIC,
women were excluded a priori if they had a history of
cancer prior to recruitment or were missing a diagnosis or
censoring date, thus leaving 345,153 participants. At the
time of this analysis, three EPIC study centers, (Granada,
Murcia and Malmo), did not provide any information on
breast tumor hormone receptor status and therefore were
excluded from this analysis (n=26,091). Women were
further excluded if they were missing questionnaire data
(n=526) or were missing data on age at menarche, age at
menopause, age at first full-term birth, ever use of OCs,
number of full-term births, age at last full-term childbirth
and duration of breastfeeding (n=7,439). This left a total
of 311,097 women with 9,456 first primary invasive breast
cancer cases from 10 countries for the present analysis.
Questionnaire data and classification of reproductive
variables
The details of standardized procedures for collecting
baseline information on the age at first and last men-
struation, parity, breastfeeding, exogenous hormone use,
and hysterectomy from the general lifestyle question-
naire has been previously reported [17,18]. Briefly, in
Greece, Italy, the Netherlands, Sweden and the United
Kingdom, age at menarche was asked in years. In the
other countries, age at menarche was asked in defined
categories (≤8, 9, 10,…, 18, 19 or >19 years). The num-
ber of full-term pregnancies (defined as the sum of all
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duced abortions were also collected at baseline, together
with the ages of the first three and last deliveries and the
ages at first and last induced or spontaneous abortions
and stillbirths. Except for Norway and the Swedish cen-
ter Umeå, where information about multiple pregnancies
was available, the number of pregnancies is overesti-
mated as multiple pregnancies were counted as different
pregnancies. The length of time between menarche and
age at first pregnancy was estimated among women who
had menarche between the ages of 8 and 20 years (time
between menarche and first full-term birth = age at first
full-term birth – age at menarche).
Women were considered postmenopausal at recruit-
ment if they had had no menstrual cycles in the last
12 months, were older than 55 years (if the menstrual
cycle history was missing), or had a bilateral oopho-
rectomy. Women who were aged 46–55 years and had
incomplete or were missing questionnaire data on men-
strual history were classified with a peri/-or of unknown
menopausal status. Women were deemed premenopausal
if they reported regular menstrual cycles in the last
12 months or if they were younger than 46 years of age
(if the menstrual cycle history was missing).
The details of standardized procedures for measuring
height and weight at EPIC study centers has also been
previously reported [19]. In most countries, height,
weight and waist and hip circumferences were measured
to the nearest centimeter and kilogram, in light clothing,
according to standardized protocols. In Norway, Umeå
and a large proportion from France, subjects’ height and
weight were measured and self-reported by the cohort
participants themselves, following detailed instructions
[17,19]. For subjects that had neither self-reported nor
measured weight or height data, the center-, age- and
gender-specific average weight and height values were
imputed for anthropometry variables used for adjust-
ment purposes only. A sensitivity analysis that restricted
the adjusted variables to those without imputation showed
similar results to those presented (data not shown).
Prospective ascertainment of breast cancer cases and the
coding of receptor status
In all countries (except for France, Germany and Greece)
incident breast cancer cases were identified using record
linkage with cancer and pathology registries. In France,
Germany and Greece, cancer occurrence was prospec-
tively ascertained through linkage with health insurance
records and regular direct contact with participants and
their next of kin, and all reported breast cancer cases were
then systematically verified against clinical and patho-
logical records. Mortality data were coded according to
the 10th Revision of the International Statistical Classifica-
tion of Diseases, Injuries, and Causes of Death (ICD-10),
and cancer incidence data were coded according to
the International Classification of Diseases for Oncology
(ICD-O-2). Invasive (primary, malignant) breast cancer
cases were classified as per the International Classification
of Diseases for Oncology (Topography C50), second revi-
sion (ICD-O-2). Breast tumor receptor status was stan-
dardized across EPIC centers using the following criteria
for a positive expression: ≥10% cells stained, any ‘plus-
system’ description, ≥20 fmol/mg, an Allred score of ≥3,
an IRS ≥2, or an H-score ≥10 [20].
Vital status was collected from regional or national
mortality registries. The last updates of endpoint data
for cancer incidence and vital status were between 2005
and 2010, depending on the center. Women were con-
sidered at risk from the time of recruitment until breast
cancer diagnosis or censoring (age at death, loss to fol-
low up, end of follow up, or diagnosis of other cancer)
respectively. A total of 7,095 breast cancer cases had
information on ER status (5,723 ER-positive, 1,372
ER-negative); of which, 5,843 had further information on
PR status (3,567 ER+PR+, 1,078 ER+PR-, 200 ER-PR+,
998 ER-PR-).
Statistical analysis
Associations between reproductive factors and the risk of
breast cancer subtype were evaluated using Cox propor-
tional hazards models to estimate hazard ratios (HR) and
95% confidence intervals (CIs). Breast cancer subtypes
were defined as jointly classified ER+PR+ or ER-PR- breast
tumors. Results for ER-positive versus ER-negative (igno-
ring PR status); and PR-positive versus PR-negative (igno-
ring ER status) were generally similar to the jointly
defined ERPR breast cancer subtypes and have been
included in Additional file 1: Table S1. Results for breast
tumors with discordant ER and PR status and unknown ER
and/or PR status have been reported in Additional file 2:
Table S2. All analyses were stratified by age at recruitment
in one-year categories and by study center, to prevent vio-
lations of the proportional-hazard assumption. Trend tests
across levels of exposure categories were performed on
the continuous categorical variables entered as ordered,
quantitative variables into the models.
Age at menarche was categorized as ≤12, 13–14
and ≥15 years and time between menarche and first full-
term childbirth as <10 and ≥10 years. Parity related vari-
ables were divided into the following categories ever vs.
never, number of full-term pregnancies (1, 2, ≥3), age
at first full-term childbirth as ≤19, 20–24, 25-29,
30-34, ≥35 years, age at last full-term childbirth since re-
cruitment as ≤24, 25–29, 30-34, ≥35 years and time since
last child birth as ≤20 and >20 years. Breastfeeding was
categorized as ever versus never, and ≤1m o n t h ,2 - 3 ,4 –6,
7–12, 13–17 and ≥18 months for total cumulative dura-
tion of breastfeeding. Dichotomized categories of ever vs.
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vs. never OC use, and current versus not currently using
OCs (at baseline) also were analyzed. The duration of OC
use was categorized into ≤1, 2–4, 5–9, and ≥10 years. Age
at menopause was divided into the categories ≤48, 49–50,
51–54 and ≥55 years.
A basic model stratified by age and center and a multi-
variable model further adjusted for body mass index (BMI
kg/m
2, as a continuous variable), height (as a continuous
variable), menopausal status at enrolment (premenopausal,
peri-/unknown menopausal, postmenopausal [natural and
surgical menopause], HRT use (premenopausal, ever use,
never use and missing in postmenopausal women only),
smoking status (current, former, never, missing), baseline
alcohol consumption (non-consumers, 0.1–6g / d a y ,
6-12 g/day, 12-24 g/day, 24-60 g/day and greater than
60 g/day, missing), physical activity (Cambridge Index:
active, moderately active, moderately inactive and inactive,
missing [21]), education level (none, primary school, tech-
nical/professional school, secondary school, longer educa-
tion including university degree, missing) were assessed.
Missing values (generally <2%) were accounted for by
creating an extra category in each covariate.
To avoid collinearity when studying the joint effect of
the number of full-term pregnancies, age at first and last
full-term childbirth and time since last childbirth, we used
the approach described by Heuch et al. [22]. In analyses
including age at last full-term childbirth and time since
last childbirth in an age adjusted model, the general age
effect was represented by the age effect among nulliparous
women. We assigned constant values for age at full-term
childbirth and time since last full-term childbirth (cor-
responding to the reference categories) to nulliparous
women, and indicator variables were introduced in the
model to ensure that the risk estimates reflected effects in
parous women only.
Differences in risk estimates of a given factor and across
breast cancer subtypes were analyzed using the data aug-
mentation method as described by Lunn and McNeil,
using a likelihood ratio test to compare the model with
and without interaction terms between the exposure of
interest and breast cancer subtype [23]. Women were con-
sidered at risk of a given breast cancer subtype until they
were diagnosed with a different competing breast cancer
subtype or were diagnosed with breast cancer and the
receptor status information was missing. These women
were censored at the time of occurrence of the competing
breast cancer subtype [23]. To assess whether breast
cancer subtype reproductive risk factors changed across
women after menopause, left and/or right side censoring
was used to count person years within defined age pe-
riods <50 years, and ≥50 years. As no differences were
observed between risk estimates of reproductive risk fac-
tors and breast cancer subtype risk across the age-bands
we report results for all women combined. A sensitivity
analysis restricting to cases with any indication of an ER
and PR expression versus a complete absence of ER and
PR expression (0% cells stained, a “-“ description (i.e. a
negative/minus symbol description), 0 fmol/mg, an Allred
score of 0, an IRS = 0, or an H-score = 0) was also per-
formed. Heterogeneity in the risk associations between
subgroups by age at diagnosis (<50 vs. ≥50 years), OC use,
center, median BMI, age at first pregnancy and ever hav-
ing breastfed were also examined using the Cochran’sQ
statistic. A previous analysis on postmenopausal HRT use
has been reported in the EPIC cohort, therefore HRT use
as a predictor of breast cancer risk by HR status was not
included in this analysis [24]. All statistical analyses were
performed using the SAS software package, version 9.2
(SAS Institute, Cary, NC).
Results
A total cohort of 311,097 women was followed for a sum
of 3,346,356 person years. Women were recruited into the
EPIC study at the median age of 51.1 years (Table 1). At
the time of recruitment, 46.5% of the women were post-
menopausal and the median age of menopause was
50.0 years. For parous women, the median age at first full-
term birth across the EPIC centers was 24.0 and the
median time between menarche and first child birth was
11.0 years. The median age at last full-term pregnancy
was 29.0 years, and a median time of 22.9 years had
passed since the last childbirth. Of the women who had
breastfed (83.8%), the median time of breastfeeding was
6.0 months for all pregnancies.
A statistically significant heterogeneity between the risk
of ER-PR- (n = 998) and ER+PR+ (n = 3,567) tumors was
observed for age at first full-term childbirth (Table 2).
While Cox regression models showed no association with
risk of ER-PR-malignancies, a first full-term childbirth
after the age of 35 was associated with an increased risk
of ER+PR+ tumors (≥35 vs. ≤19 years HR: 1.47 [95%
CI 1.15-1.88] ptrend <0 . 0 0 1 ,Phet =0 . 0 3 ) .
For ER-PR- breast tumors, similar risk associations to
ER+PR+ breast tumors were observed with increasing
menarcheal age (≥15 vs. ≤ 13 years ER-PR- HR: 0.84 [95%
CI 0.69-1.03], Ptrend =0.17; ER+PR+ HR: 0.76 [95%
CI 0.68-0.85], Ptrend <0.001; Phet = 0.48), and among par-
ous women, with longer time between menarche and first
full-term childbirth (≥10 vs. < 10 years ER-PR- HR: 1.15
[95% CI 0.99-1.34], Ptrend =0.09; ER+PR+ HR: 1.22 [95%
CI 1.12-1.33], Ptrend <0.001; Phet = 0.52). Although the
relative risk estimates for ER-PR- breast malignancies were
in a similar direction to the ER+PR+ tumors and no sta-
tistical heterogeneity between the breast cancer subtypes
was observed, it should be noted that risk associations for
ER-PR- malignancies were weaker in magnitude and failed
to reach statistical significance.
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and time since last full-term childbirth were generally not
associated with the risk of ER-PR- malignancies but were
associated with ER+PR+ tumors, however no statistical
heterogeneity between the breast cancer subtypes was
observed. Moreover, OC use, duration of OC use, breast
feeding, ever having an abortion (spontaneous or induced)
and age at menopause showed no significant associations
with either ER-PR- or ER+PR+ breast cancer.
When all of the pregnancy related variables were
examined together in the same model, risk associations
for an increased number of full-term births, and later
first and last full-term childbirth with ER-PR- tumors
appeared to slightly strengthen; however they remained
statistically not significant and had wider confidence
intervals (Table 3). When analyses were restricted to post-
menopausal women, the risk estimates for a later age at
first full-term childbirth with ER+PR+ tumors were
stronger (≥35 vs. ≤19 years HR: 1.64 [95% CI 1.05-2.56]
ptrend=0.002) compared to the estimates for all the
women combined (≥35 vs. ≤19 years HR: 1.30 [95%
CI 0.95-1.79] ptrend=0. 02 ).
Subgroup analyses showed no heterogeneity in most of
the risk estimates of the reproductive variables for ER-PR-
and ER+PR+ tumors (data not shown), with the exception
of the duration of breastfeeding by age at first birth among
parous women (Pheterogeneity = 0.002). Among women who
had their first full-term childbirth before the age of 25, a
longer duration of total breastfeeding showed an indi-
cation of a decreased risk association with ER+PR+
tumors (≥18vs. ≤ 1 month HR: 0.86 [95% CI 0.67-1.10],
Ptrend = 0.01). In contrast, among women who had their
first full-term childbirth after the age of 25, a longer cu-
mulative duration of breastfeeding was associated with
a particular increased risk of ER+PR+ tumors (≥18vs. ≤
1 month HR: 1.50 [95% CI 1. 13–1.99], Ptrend =0 . 0 0 5 ) .
For ER-PR- tumors, risk estimates in the similar direc-
tion to the ER+PR+ tumors were observed, however
statistically not significant (first childbirth before the
age of 25, ≥18vs. ≤ 1 month of breast feeding HR: 0.90
[95% CI 0.58-1.39], Ptrend = 0.89; first childbirth after
the age of 25, ≥18vs. ≤ 1 month of breast feeding HR:
1.31 [95% CI 0.72-2.39], Ptrend = 0.41).
In the sensitivity analysis restricted to cases with any
indication of a positive ER and PR expression versus a
complete absence of ER and PR expression with repro-
ductive factors showed similar patterns with risk of joint
ER+PR+ and ER-PR- breast cancer subtypes (data not
shown).
Discussion
Our results showed a significantly heterogeneous risk as-
sociation for age at first full-term pregnancy by receptor
status of the tumor, where later first full-term childbirth
was associated with increased risk of ER+PR+ tumors
but not with risk of ER-PR- tumors. Menarcheal age and
time period between menarche and first full-term child-
birth showed suggestively similar risk associations with
both ER-PR- and ER+PR+ tumors, however the risk esti-
mates for ER-PR- tumors were generally weaker than for
their ER+PR+ counterparts and only borderline signifi-
cant. Although the heterogeneity between breast cancer
subtypes was not statistically significant, other parity
Table 1 Baseline characteristics of 311,097 EPIC cohort
participants
Study variables All women
(n= 311,097)
Age at recruitment (median, range) 51.1 (19.9-98.5)
Age end of follow-up (1st tumor) (median, range) 62.0 (21.2-102.4)
Years of follow up (median, range) 11.3 (0.0-16.7)
Menopausal status
Premenopausal 108,084 (34.7)
Peri/Unknown 58,345 (18.8)
Postmenopausal 144,668 (46.5)
Age at menarche (median, range) 13.0 (8.0-20.0)
Age at menopause (median, range)
1 50.0 (16.0-67.0)
Ever full-term pregnancy (yes, %) 255,877 (84.5)
Age at first full-term pregnancy (median, range)
2 24.0 (12.0-56.0)
Time between menarche and first pregnancy (years)
(median, range)
2
11.0 (0.0-41.0)
Number of full-term pregnancies
2
1 child 46,572 (18.8)
2 children 122,590 (49.4)
≥3 children 78,983 (31.8)
Breastfeeding (yes, %)
2 200,885 (83.8)
Duration of breastfeeding, all pregnancies (months)
(median, range)
2,3
6.0 (0.2-286.4)
Age at last full-term pregnancy (median, range)
2 29.0 (13.0-56.0)
Time since last full-term pregnancy (years)
(median, range)
2
22.9 (0.0-69.1)
Ever had an abortion (yes, %)
4 87,130 (40.1)
Oral contraceptive (OC) use
Never OC user 125,229 (41.4)
Past OC user 160,926 (53.2)
Current OC user 16,560 (5.5)
Age when you started using the pill
(median, range)
5
24.0 (8.0-50.0)
Duration of using the pill (years) (median, range)
5 5.0 (1.0-15.0)
1In natural and surgically menopausal women only.
2In parous women only.
3In women who breast-fed only.
4Both spontaneous and induced abortions.
5In women who ever used OC.
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Age and center stratified Multivariable adjusted
1
ER+PR+ ER-PR- ER+PR+ ER-PR-
(n = 3567) (n = 998) (n = 3567) (n = 998)
Reproductive factor Cases HR 95% CI Cases HR 95% CI Cases HR 95% CI Cases HR 95% CI
Age at menarche
<13 years 1373 1.00 Reference 376 1.00 Reference 1373 1.00 Reference 376 1.00 Reference
14 years 1717 0.96 (0.90-1.04) 481 0.98 (0.86-1.13) 1717 0.96 (0.89-1.03) 481 0.97 (0.85-1.12)
≥15 years 439 0.76 (0.68-0.85) 135 0.85 (0.69-1.04) 439 0.76 (0.68-0.85) 135 0.84 (0.69-1.03)
P for trend <0.001 0.17 <0.001 0.17
Subtype heterogeneity
2 0.44 0.48
Age at menopause
3
≤48 years 464 1.00 Reference 135 1.00 Reference 464 1.00 Reference 135 1.00 Reference
49–50 years 397 1.10 (0.95-1.26) 116 1.09 (0.84-1.41) 397 1.12 (0.98-1.29) 116 1.09 (0.84-1.42)
51–54 years 280 1.04 (0.89-1.21) 63 0.88 (0.64-1.20) 280 1.06 (0.91-1.24) 63 0.87 (0.64-1.20)
≥55 years 121 1.19 (0.97-1.47) 32 1.06 (0.71-1.58) 121 1.17 (0.95-1.44) 32 1.03 (0.69-1.54)
P for trend 0.18 0.79 0.18 0.79
Subtype heterogeneity
2 0.40 0.34
Ever a full-term birth
No 446 1.00 Reference 115 1.00 Reference 446 1.00 Reference 115 1.00 Reference
Yes 2994 0.86 (0.77-0.95) 843 0.97 (0.80-1.19) 2994 0.87 (0.78-0.96) 843 0.98 (0.80-1.20)
P for significance 0.003 0.78 0.01 0.78
Subtype heterogeneity
2 0.92 0.88
Number of full-term childbirths
4
1 child 612 1.00 Reference 160 1.00 Reference 612 1.00 Reference 160 1.00 Reference
2 children 1497 0.92 (0.84-1.01) 432 1.02 (0.85-1.22) 1497 0.92 (0.84-1.01) 432 1.01 (0.84-1.22)
>3 children 840 0.77 (0.69-0.85) 244 0.89 (0.72-1.09) 840 0.76 (0.68-0.85) 244 0.89 (0.73-1.10)
P for trend <0.001 0.19 <0.001 0.19
Subtype heterogeneity
2 0.22 0.20
Age at first full-term childbirth
4
≤19 years 357 1.00 Reference 103 1.00 Reference 357 1.00 Reference 103 1.00 Reference
20–24 years 1369 1.06 (0.94-1.20) 431 1.20 (0.97-1.50) 1369 1.07 (0.95-1.21) 431 1.20 (0.96-1.50)
25–29 years 912 1.20 (1.06-1.36) 242 1.16 (0.92-1.47) 912 1.22 (1.07-1.39) 242 1.17 (0.92-1.50)
30–34 years 275 1.35 (1.15-1.59) 61 1.10 (0.80-1.52) 275 1.39 (1.18-1.64) 61 1.12 (0.81-1.56)
≤35 years 82 1.44 (1.13-1.83) 14 0.91 (0.52-1.60) 82 1.47 (1.15-1.88) 14 0.93 (0.53-1.65)
P for trend <0.001 0.96 <0.001 0.96
Subtype heterogeneity
2 0.02 0.03
Time between menarche and first full-term childbirth
4
<10 years 837 1.00 Reference 257 1.00 Reference 837 1.00 Reference 257 1.00 Reference
≥10 years 2133 1.21 (1.12-1.31) 592 1.14 (0.98-1.32) 2133 1.22 (1.12-1.33) 592 1.15 (0.99-1.34)
P for significance <0.001 0.09 <0.001 0.09
Subtype heterogeneity
2 0.49 0.52
Age at last full-term childbirth
4
≤24 years 463 1.00 Reference 138 1.00 Reference 463 1.00 Reference 138 1.00 Reference
25–29 years 1058 0.98 (0.88-1.10) 321 1.01 (0.82-1.23) 1058 0.98 (0.88-1.10) 321 1.01 (0.82-1.23)
30–34 years 984 1.07 (0.95-1.20) 263 0.97 (0.78-1.19) 984 1.07 (0.96-1.20) 263 0.98 (0.79-1.21)
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≥35 years 490 1.11 (0.97-1.26) 130 1.01 (0.79-1.29) 490 1.12 (0.98-1.28) 130 1.03 (0.80-1.33)
P for trend 0.03 0.90 0.02 0.90
Subtype heterogeneity
2 0.24 0.29
Time since last full-term childbirth
4
≤20 years 1043 1.00 Reference 300 1.00 Reference 1043 1.00 Reference 300 1.00 Reference
>20 years 1952 0.87 (0.78-0.96) 552 1.00 (0.82-1.22) 1952 0.86 (0.77-0.95) 552 0.98 (0.81-1.20)
P for significance 0.01 0.98 0.01 0.98
Subtype heterogeneity
2 0.20 0.24
Ever breast-fed
4
No 538 1.00 Reference 152 1.00 Reference 538 1.00 Reference 152 1.00 Reference
Yes 2317 0.99 (0.90-1.09) 642 0.97 (0.81-1.16) 2317 0.99 (0.89-1.09) 642 0.98 (0.81-1.17)
P for significance 0.82 0.74 0.76 0.74
Subtype heterogeneity
2 0.85 0.93
Total cumulative breastfeeding duration
4,5
<1 month 249 1.00 Reference 72 1.00 Reference 249 1.00 Reference 72 1.00 Reference
1–3 months 602 1.04 (0.89-1.20) 155 0.91 (0.69-1.21) 602 1.04 (0.89-1.20) 155 0.91 (0.69-1.21)
4–6 months 460 0.97 (0.83-1.14) 137 0.98 (0.74-1.32) 460 0.97 (0.83-1.14) 137 0.99 (0.74-1.32)
7–12 months 487 0.97 (0.83-1.13) 132 0.91 (0.68-1.22) 487 0.97 (0.83-1.13) 132 0.91 (0.68-1.23)
13–17 months 182 0.91 (0.75-1.11) 62 1.10 (0.78-1.57) 182 0.92 (0.75-1.12) 62 1.12 (0.79-1.60)
≥18 months 293 1.09 (0.91-1.31) 77 1.04 (0.73-1.46) 293 1.11 (0.92-1.33) 77 1.07 (0.75-1.51)
P for trend 0.99 0.54 0.90 0.54
Subtype heterogeneity
2 0.58 0.53
Ever an abortion
6
No 1552 1.00 Reference 435 1.00 Reference 1552 1.00 Reference 435 1.00 Reference
Yes 1016 1.00 (0.92-1.08) 293 1.00 (0.86-1.16) 1016 0.99 (0.91-1.07) 293 1.00 (0.86-1.16)
P for significance 0.97 0.98 0.72 0.98
Subtype heterogeneity
2 0.97 0.86
OC use at recruitment
Never OC user 1477 1.00 Reference 379 1.00 Reference 1477 1.00 Reference 379 1.00 Reference
Past OC user 1839 1.00 (0.93-1.08) 548 1.11 (0.96-1.28) 1839 0.97 (0.90-1.05) 548 1.09 (0.94-1.26)
Current OC user 108 1.20 (0.97-1.47) 33 1.08 (0.73-1.59) 108 1.19 (0.96-1.47) 33 1.09 (0.74-1.63)
P for trend 0.42 0.20 0.95 0.20
Subtype heterogeneity
7 0.34 0.30
Age started OC
8
≤24 years 899 1.00 Reference 292 1.00 Reference 899 1.00 Reference 292 1.00 Reference
25–29 years 335 0.86 (0.75-0.99) 94 0.86 (0.66-1.11) 335 0.87 (0.76-1.00) 94 0.86 (0.66-1.11)
30–34 years 303 0.91 (0.78-1.07) 90 0.92 (0.69-1.23) 303 0.93 (0.79-1.08) 90 0.92 (0.69-1.22)
≥35 years 265 1.07 (0.90-1.28) 73 0.97 (0.70-1.36) 265 1.09 (0.91-1.30) 73 0.97 (0.70-1.36)
P for trend 0.83 0.75 0.67 0.75
Subtype heterogeneity
2 0.70 0.61
Duration of OC use
8
1 year or less 396 1.00 Reference 114 1.00 Reference 396 1.00 Reference 114 1.00 Reference
2–4 years 450 1.02 (0.89-1.17) 116 0.86 (0.66-1.12) 450 1.03 (0.89-1.18) 116 0.86 (0.67-1.12)
5–9 years 426 1.06 (0.92-1.22) 122 0.97 (0.75-1.26) 426 1.06 (0.92-1.22) 122 0.97 (0.75-1.27)
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≥10 years 521 1.02 (0.89-1.17) 187 1.11 (0.87-1.41) 521 1.02 (0.89-1.18) 187 1.11 (0.87-1.42)
P for trend 0.70 0.21 0.68 0.21
Subtype heterogeneity
2 0.36 0.37
1Stratified by age at recruitment and center and further adjusted for BMI, height, menopausal status at enrolment, HRT use, physical activity, smoking status,
alcohol consumption and attained level of education;
2heterogeneity between ER+PR+ and ER-PR- tumors was assessed on the trend score using the data
augmentation method as described by Lunn and McNeil;
3in postmenopausal women only;
4in parous women only;
5in women who breast-fed only;
6in both
spontaneous and induced abortions;
7heterogeneity between ER+PR+ and ER-PR- tumors was assessed on the unordered categorical variable of never, past and
current OC use using the data augmentation method as described by Lunn and McNeil;
8in women who ever used OC.
Table 3 A mutually adjusted model of pregnancy related variables and risk of ER+PR+ vs. ER-PR- breast cancer
Age and center stratified Multivariable adjusted
1 Postmenopausal women
2
ER+PR+ ER-PR- ER+PR+ ER-PR- ER+PR+ ER-PR-
(n = 3387) (n = 944) (n = 3387) (n = 944 ) (n = 1755) (n = 477)
Reproductive factor HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Number of full-term childbirths
3
1 child 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
2 children 0.93 (0.84-1.03) 0.97 (0.80-1.19) 0.93 (0.84-1.03) 0.98 (0.80-1.19) 0.96 (0.83-1.10) 0.90 (0.69-1.19)
≥3 children 0.77 (0.68-0.87) 0.83 (0.66-1.05) 0.77 (0.68-0.87) 0.84 (0.66-1.06) 0.79 (0.67-0.93) 0.90 (0.65-1.22)
P for trend <0.001 0.09 <0.001 0.10 0.002 0.54
Subtype heterogeneity
4 0.53 0.47 0.22
Age at first full-term childbirth
3
≤19 years 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
20–24 years 1.05 (0.92-1.19) 1.11 (0.88-1.40) 1.05 (0.92-1.19) 1.10 (0.87-1.39) 1.17 (0.97-1.40) 1.14 (0.82-1.59)
25–29 years 1.16 (0.99-1.35) 0.96 (0.72-1.28) 1.16 (0.99-1.36) 0.96 (0.72-1.28) 1.32 (1.05-1.64) 1.02 (0.68-1.54)
30–34 years 1.24 (1.00-1.53) 0.83 (0.55-1.25) 1.24 (1.00-1.53) 0.83 (0.55-1.25) 1.57 (1.16-2.11) 0.88 (0.49-1.57)
≥35 years 1.32 (0.96-1.82) 0.69 (0.35-1.36) 1.30 (0.95-1.79) 0.69 (0.35-1.36) 1.64 (1.05-2.56) 0.81 (0.32-2.03)
P for trend 0.02 0.19 0.02 0.19 0.002 0.51
Subtype heterogeneity
4 0.03 0.03 0.05
Age at last full-term childbirth
3
Less than 25 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Between 25 and 30 0.90 (0.80-1.02) 1.15 (0.93-1.44) 0.90 (0.80-1.02) 1.16 (0.93-1.44) 0.87 (0.74-1.02) 1.13 (0.83-1.53)
Between 30 and 35 0.97 (0.83-1.13) 1.33 (1.00-1.77) 0.97 (0.84-1.13) 1.33 (1.00-1.77) 0.85 (0.69-1.04) 1.27 (0.86-1.86)
Greater than 35 0.89 (0.72-1.09) 1.29 (0.88-1.90) 0.89 (0.73-1.10) 1.30 (0.88-1.91) 0.83 (0.63-1.10) 1.39 (0.83-2.34)
P for trend 0.53 0.10 0.58 0.09 0.18 0.18
Subtype heterogeneity
4 0.17 0.17 0.09
Time since last full-term childbirth
3
≤20 years 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
>20 years 0.87 (0.77-0.98) 1.01 (0.81-1.26) 0.86 (0.77-0.97) 1.00 (0.80-1.25) 0.90 (0.73-1.12) 1.10 (0.74-1.65)
P for significance 0.02 0.94 0.02 0.99 0.35 0.63
Subtype heterogeneity
4 0.24 0.24 0.29
1Stratified by age at recruitment and center and further adjusted for BMI, height, menopausal status at enrolment, HRT use, physical activity, smoking status,
alcohol consumption and attained level of education;
2stratified by age at recruitment and center and further adjusted for BMI, height, HRT use, physical activity,
smoking status, alcohol consumption and attained level of education;
3mutually adjusted for the pregnancy related variables in this table;
4heterogeneity between
ER+PR+ and ER-PR- tumors was assessed on the trend score using the data augmentation method as described by Lunn and McNeil.
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birth, number of full-term childbirths, age- and time
since last full-term childbirth) were associated only with
ER+PR+ malignancies. Finally, the factors related to
breastfeeding and OC use were generally not associated
with HR-positive or HR-negative breast cancer risk.
Previous prospective studies investigating the asso-
ciation of reproductive factors with HR-positive breast
cancer have shown relatively consistent inverse risk asso-
ciations with increasing menarcheal age, ever having a
full-term childbirth and particularly a full-term childbirth
at an early age [3,9,14,25]. However, consensus on the as-
sociations with HR-negative tumors has not been reached
because previous prospective studies have lacked sufficient
sample sizes [3,9,26] and because of the heterogeneous
nature of HR-negative subtypes [1]. A more recent study
within the Women’s Health Initiative [14] showed that
ever having a full-term childbirth was associated with an
increased risk of triple-negative breast cancer (ER-, PR-
and HER2-) (n = 307) and the positive association was
strengthened with an increasing number of full-term
births. We were unable to confirm the positive risk asso-
ciation with ever having a full-term childbirth and increa-
sing number of full-term pregnancies with HR-negative
tumors, however we did not have information on triple
negative tumors.
We observed for both ER-PR- and ER+PR+ tumors,
similar risk associations with increasing menarcheal age
and a longer time between menarche and first full-term
childbirth. A recent study within the EPIC cohort previ-
ously reported on the association of menarche with both
ER-PR- and ER+PR+ tumors within the context of child-
hood growth and earlier sexual maturity [27]. This study
extends onto this study of menarche and growth and fo-
cuses on the time period between sexual maturity and first
full-term pregnancy, thus illustrating the complex and
entwined nature of endocrine-sensitive tumors with
hormones during different life phases of growth, sexual
maturity and reproduction. The inverse association of
menarcheal age with increased breast cancer risk is
thought to be resultant of a longer exposure to estrogens
during a women’s reproductive life [2] but may also reflect
early pubertal years characterized by more intensive and
increased exposure to estrogen [27,28]. Estrogens have
been long established to have a late-stage growth promo-
ting effect on estrogen sensitive tumors [29], however, evi-
dence suggests that estrogens may also play an important
role in earlier developmental stages of both HR-positive
and -negative tumor types [30]. Mammary stem cells have
been shown to respond to sex steroid hormones without
having a clear expression of an ER or PR [31]. Further,
the EPIC cohort, showed that pre-diagnostic levels of
estrogens were associated with both HR-negative and
HR-positive postmenopausal breast cancer [20]. The longer
time between menarche and a women’s first full-term
childbirth would equate to a longer period of time with
undifferentiated breast epithelial tissue and a shorter
period of time that the breast is resistant to malignant
transformation [26] and thus may have etiological impor-
tance in the formation of ER-PR- tumors as well.
We observed a significantly different risk association
for a later age at first full-term childbirth with risk of
HR-negative and HR-positive tumors, whereas the asso-
ciations for parity related factors (such as ever having a
full-term childbirth, age a last full-term childbirth and
time since last full-term childbirth) appeared to aggregate
around HR-positive tumors. The role of a pregnancy with
the risk of breast cancer is thought to stem from two
major avenues, firstly, hormonal changes before and after
pregnancy and secondly [26], dramatic structural changes
in the ductal system of the breast after pregnancy [26,32].
A full-term childbirth is associated with a long term post-
pregnancy reduction in levels of circulating hormones
[26]. Before a women’s first pregnancy the breast contains
a high proportion of undifferentiated ducts and associated
alveolar buds. Complete differentiation only occurs during
pregnancy and lactation via complex morphological, phy-
siological, and molecular changes [32]. Terminally diffe-
rentiated epithelial cells are more resistant to carcinogenic
influences because of lower proliferation rates and longer
DNA repair phases [26]. The distinct inverse risk asso-
ciation for an earlier age at first full-term childbirth with
ER+PR+ disease could be due to a shorter exposure to
higher levels of ovarian estrogens and a shorter period of
time of undifferentiated breast epithelial cells.
Recent prospective studies have reported reduced risk
associations with breastfeeding with both ER-PR- and
ER+PR+ breast cancer [3,14]. In the current analysis,
we also observed an inverse risk association for both
ER-PR- and ER+PR+ malignancies with a longer cumu-
lative duration of breastfeeding however, this was re-
stricted to women who had an early full-term childbirth.
In contrast to the recent studies, among women who
had a later first full-term childbirth, an increased risk
with ER-PR- and ER+PR+ breast tumors with a longer
total duration of breastfeeding was observed. Breast-
feeding is thought to protect a woman from developing
breast cancer by increasing breast differentiation, post-
poning the return of the ovulatory menstrual cycle post-
pregnancy, and/or changing the hormonal environment
of the breast [9,26,32]. The inverse risk association of
HR-negative and HR-positive tumors with breastfeeding
coupled with a longer duration among young first time
mothers could convey a similar protection. In addition,
lactation at a younger age would also mean a shorter
period of undifferentiated breast epithelial tissue [26].
OC use has been extensively studied by many epidemio-
logical studies and most studies have found either no
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breast cancer, particularly among very young women
and recent OC users [26]. More recent case–control
studies investigating the risk of HR-defined breast can-
cer have started showing relationships of OC use with
HR-negative breast cancer [33-37]. In the current study,
we were unable to confirm significant risk associations
o fe v e rO Cu s ea n dal o n g e rd u r a t i o no fO Cu s ew i t h
HR-negative tumors. There were only a small number
of baseline OC users within this analytical cohort, and
unfortunately within the EPIC cohort, information of
dose or type of OC used, date of last use and infor-
mation on changes to OC use after baseline are not
available. Similarly, the estrogens and progestins in oral
contraceptives differ in type and concentration [37] and
this could be hiding a risk association.
Major strengths of this study are its prospective de-
sign and large number of incident cases with receptor
information. The large case numbers allowed an in-
depth analysis of reproductive-related relative risks,
describing risk associations among women of predo-
minantly premenopausal and postmenopausal age. The
large case numbers also enabled us to examine sub-
group effects such as age at first birth, age at diagnosis,
BMI and breastfeeding. To our knowledge, this analysis
uses the largest number of incident cases of ER-PR-
malignancies, although future prospective studies with a
greater number of ER-PR- cases are necessary to
characterize the associations, which are of substantially
smaller magnitude when compared to their HR-positive
counterparts. Our study does have its limitations. The
determination of ER and PR status in breast tumors has
become a standard part of breast cancer diagnosis and
is used to predict endocrine therapy response [4]. While
a number of studies have shown that the classification
of the ER and PR in tumors is relatively robust [38,39],
the accuracy of classifying an ER or PR-negative tumor
remains controversial [40,41]. In the analysis that com-
pared women with a complete absence of ER and PR
expression to women with any indication of an ER and
PR positive expression, ER-PR- risk estimates remained
unchanged. Furthermore, proportions of ER and PR–
negative tumors in the EPIC cohort are in line with pre-
vious reports [13,42]. In addition, the inclusion of PR
provides an indication of a functional estrogen pathway
[ 2 ]a n dt h u saj o i n tE R - P R -m a yb em o r er e f l e c t i v eo fa
true ER-negative tumor. At the time of this study, add-
itional information on HER2 expression to determine
breast cancer subtypes into more detailed molecular
sub-classifications could not be completed because of
insufficient information on HER2. However, as the rou-
tine assessment of HER2 is relatively more recent than
ER and PR assessment, future cohort analyses will be
able to include HER2.
Conclusions
In conclusion, our study provides evidence that later age at
first full-term childbirth is associated with an increased risk
of ER+PR+ tumors but not with ER-PR- tumors. Moreover,
age at menarche and time between menarche and first full-
term childbirth may be associated with the etiology of both
HR-negative and HR-positive malignancies, although asso-
ciations were only borderline significant for HR-negative
tumors. Further studies with more incident cases of ER-PR-
tumors are needed to provide more precise risk estimation
for reproductive factors with HR-negative tumors.
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